Aura Biosciences Inc (AURA)

Over the past six months, Aura Biosciences' stock price has decreased. Key events include positive Phase 2 results for bel-sar, the release of Q3 2025 financial results with guidance on the Phase 3 CoMpass trial, participation in healthcare conferences, and earnings reports. Analyst ratings for Aura Biosciences have a consensus of "Buy" with a price target of $20.50.

As a clinical-stage biotechnology company, Aura Biosciences, Inc. does not currently experience demand seasonality for its products or services. Demand for future products will depend on medical need and regulatory approvals.

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision immunotherapies for solid tumors, particularly early-stage choroidal melanoma. Their lead product candidate, belzupacap sarotalocan (bel-sar; AU-011), is in late-stage clinical development and is also being explored for other ocular oncology indications and bladder cancer.

Aura Biosciences, Inc. operates exclusively within the United States, with offices in Cambridge and Boston, MA. However, its clinical trials, including the Phase 3 CoMpass trial, are enrolling patients globally, including in the United States and Europe.

Aura Biosciences' brand reputation has been positively influenced by clinical development progress and positive trial data for bel-sar. However, concerns exist regarding ongoing operating losses and challenges in recruitment for the Phase 3 CoMpass trial, which could lead to development delays.

Aura Biosciences, Inc. has a mixed ownership structure including institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock, while insiders and public/individual investors hold smaller percentages. Major institutional owners include Matrix Capital Management Company, LP, Frazier Life Sciences Management, L.P., and BlackRock, Inc. Christopher J. Burke owns the most shares among individual investors.